Results 61 to 70 of about 16,538 (257)

METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246

open access: yesCell Death Discovery, 2021
Ovarian cancer is a common gynecological malignant tumor with a high mortality rate and poor prognosis. There is inadequate knowledge of the molecular mechanisms underlying ovarian cancer.
Xuehan Bi   +7 more
doaj   +1 more source

METTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer

open access: yesAdvanced Science, EarlyView.
GC cells enhance glutamine accumulation by upregulating SLC1A5 expression. This upregulation not only boosts GC cell proliferation, but also outcompetes CD8+ T cells for glutamine and suppresses their antitumor immunity. Mechanistically, METTL7A deficiency in GC induces SLC1A5 overexpression via an m6A‐dependent pathway and N‐glycosylation ...
Mingjun Sun   +16 more
wiley   +1 more source

PROTAC degraders of the METTL3-14 m6A-RNA methyltransferase [PDF]

open access: yes
Methylation of adenine N6 (m6A) is the most frequent RNA modification. On mRNA, it is catalyzed by the METTL3-14 heterodimer complex which plays a key role in acute myeloid leukemia (AML) and other types of blood cancers and solid tumors.
Valeria, Romanucci   +9 more
core   +2 more sources

METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4

open access: yesFrontiers in Bioscience-Landmark
Background: Osteosarcoma cells are prone to metastasis, and the mechanism of N6-methyladenosine (m6A) methylation modification in this process is still unclear.
Xi-song Huo   +5 more
doaj   +1 more source

TRIM28‐Derived Peptide Exerts Anti‐Tumor Roles by Stabilizing Tumor Suppressive BRD7 Protein in Multiple Cancers

open access: yesAdvanced Science, EarlyView.
An α‐helical peptide, TAB12, designed to mimic the TRIM28 binding interface, competitively disrupts the TRIM28‐BRD7 interaction, thereby blocking ubiquitin‐mediated degradation of the tumor suppressor BRD7. This stabilization unleashes potent anti‐tumor effects across multiple tumor types with a favorable safety profile, offering a feasible strategy ...
Qingqing Wei   +10 more
wiley   +1 more source

METTL3 knockout in U2OS cells also appears to be incomplete.

open access: yes, 2022
(A) METTL3 KO U2OS cells have persistent m6A. METTL3 KO U2OS cells have been reported to have 60% the levels of m6A found in control U2OS cells [24]. We reconfirmed this with mass spectrometry measurements of m6A, which showed that METTL3 KO U2OS cells ...
Hui Xian Poh (13118985)   +3 more
core   +1 more source

METTL3 blocked the progression of diabetic retinopathy through m6A-modified SOX2

open access: yesOpen Medicine
We aimed to explore the regulatory effects of methyltransferase-like 3 (METTL3) on diabetic retinopathy (DR) by regulating the m6A modification of SOX2 mRNA and elucidating the underlying molecular mechanism.
Chen Xiujuan   +4 more
doaj   +1 more source

A Rare De Novo Missense Mutation in IFT122 Confers a Genetic Susceptibility Factor of Idiopathic Pediatric Uveitis Via Trio‐based Whole‐Exome Sequencing

open access: yesAdvanced Science, EarlyView.
A rare de novo IFT122‐A773E variant is identified in idiopathic pediatric uveitis and shown to exacerbate retinal inflammation and barrier dysfunction. Mechanistically, the variant enhances IFT43 interaction, elevates calcium signaling, and activates the MEK/ERK/FRA1 axis, revealing a previously unrecognized cilia‐associated pathway that may increase ...
Qian Zhou   +18 more
wiley   +1 more source

METTL3 stabilizes HDAC5 mRNA in an m6A-dependent manner to facilitate malignant proliferation of osteosarcoma cells

open access: yesCell Death Discovery, 2022
Osteosarcoma (OS) is a prevalent primary bone sarcoma. Methyltransferase-like 3 (METTL3) is dysregulated in human malignancies. This study explored the mechanism of METTL3 in OS cell proliferation.
Renbing Jiang   +5 more
doaj   +1 more source

METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner

open access: yesFrontiers in Oncology, 2021
Acquired chemoresistance is a major limiting factor in the clinical treatment of glioblastoma (GBM). However, the mechanism by which GBM acquires therapeutic resistance remains unclear.
Jia Shi   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy